ReShape LifesciencesRSLS
About: Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
Employees: 31
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
1,089% more capital invested
Capital invested by funds: $7.17K [Q3] → $85.2K (+$78.1K) [Q4]
2.44% more ownership
Funds ownership: 0.25% [Q3] → 2.69% (+2.44%) [Q4]
10% less funds holding
Funds holding: 10 [Q3] → 9 (-1) [Q4]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Research analyst outlook
We haven’t received any recent analyst ratings for RSLS.
Financial journalist opinion
Based on 3 articles about RSLS published over the past 30 days









